Categories: HealthcareNews

Dr. Amir Bajoghli and Team Publish New Case Study on Aquagenic Urticaria in BMJ Journals

MCLEAN, VA / ACCESSWIRE / December 10, 2024 / Dr. Amir Bajoghli and his colleagues have recently published an insightful case study in BMJ Journals, titled Aquagenic Urticaria in an Adolescent: Differential Diagnosis and Management.” The study examines a rare case of aquagenic urticaria and underscores the importance of accurate diagnosis and effective management strategies for this unusual condition.

Aquagenic urticaria is a rare form of chronic-inducible urticaria, triggered by direct contact with water. Unlike typical urticaria, aquagenic urticaria is characterized by small, raised wheals that appear with a distinctive red halo. This condition can often be challenging to diagnose due to its unusual trigger and varied presentations, leading to potential delays in treatment. The case study presented by Dr. Bajoghli and his team highlights an adolescent male patient with aquagenic urticaria, bringing attention to the complexities involved in diagnosing and managing this rare disorder.

“We are pleased to share our findings with the medical community, as aquagenic urticaria remains a rare and often misunderstood condition,” said Dr. Amir Bajoghli. “Our goal is to enhance awareness and understanding of this unique form of urticaria, which can significantly impact quality of life for those affected. Accurate diagnosis and effective management are essential for providing patients with relief.”

Dr. Amir Bajoghli and his co-authors, Ecem Parlak and senior author Dr. Mehdi Bajoghli, emphasize the role of differential diagnosis in distinguishing aquagenic urticaria from other forms of urticaria. The study also outlines potential management approaches for healthcare professionals, offering a valuable resource for clinicians who may encounter similar cases in their practice.

For more details, the full publication can be accessed through BMJ Journals. For inquiries or additional information on aquagenic urticaria and other dermatological conditions, please contact Dr. Bajoghli at Skin & Laser Dermatology Center.

About Skin & Laser Dermatology Center

Skin & Laser Dermatology Center is a premier medical and cosmetic dermatology practice with locations in McLean and Woodbridge, Virginia. Led by Dr. Amir Bajoghli, the center offers a comprehensive range of services, including treatments for skin conditions such as acne, eczema, and rosacea, as well as cosmetic procedures for brown spots, wrinkles, and facial rejuvenation. The practice is dedicated to providing the highest standard of care, utilizing the latest technologies and techniques in the field of dermatology.

Dr. Amir Bajoghli can be reached at either of his Virginia offices:

McLean:
1359 Beverly Rd., 2nd Floor
McLean, VA 22101
(703) 893-1114

Woodbridge:
2200 Opitz Blvd., Suite 100
Woodbridge, VA 22191
(703) 492-4140

Contact Information
Jill K
PR
hi@featureddoctor.com

SOURCE: Skin & Laser Dermatology Center

View the original press release on accesswire.com

Staff

Recent Posts

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

22 hours ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

22 hours ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

22 hours ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

22 hours ago

Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…

22 hours ago

Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…

22 hours ago